JP2017529067A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529067A5 JP2017529067A5 JP2017506890A JP2017506890A JP2017529067A5 JP 2017529067 A5 JP2017529067 A5 JP 2017529067A5 JP 2017506890 A JP2017506890 A JP 2017506890A JP 2017506890 A JP2017506890 A JP 2017506890A JP 2017529067 A5 JP2017529067 A5 JP 2017529067A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding protein
- seq
- chain domain
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 26
- 108091000831 antigen binding proteins Proteins 0.000 claims 26
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 14
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 125000000539 amino acid group Chemical group 0.000 claims 5
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 3
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 claims 1
- 102000023732 binding proteins Human genes 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000056982 human CD33 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/002177 WO2015018527A1 (en) | 2013-08-07 | 2014-08-07 | ANTIBODY BINDING SITES SPECIFIC FOR EGFRvIII |
| EPPCT/EP2014/002177 | 2014-08-07 | ||
| EP15154772.6 | 2015-02-11 | ||
| EP15154772.6A EP2982693A1 (en) | 2014-08-07 | 2015-02-11 | CD3 binding domain |
| PCT/EP2015/068070 WO2016020444A1 (en) | 2014-08-07 | 2015-08-05 | Cd3 binding domain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017529067A JP2017529067A (ja) | 2017-10-05 |
| JP2017529067A5 true JP2017529067A5 (Direct) | 2018-09-13 |
| JP6669722B2 JP6669722B2 (ja) | 2020-03-18 |
Family
ID=52468915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506890A Active JP6669722B2 (ja) | 2014-08-07 | 2015-08-05 | Ｃｄ３結合ドメイン |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10066015B2 (Direct) |
| EP (2) | EP2982693A1 (Direct) |
| JP (1) | JP6669722B2 (Direct) |
| CN (1) | CN107001468B (Direct) |
| AU (1) | AU2015299039B2 (Direct) |
| BR (1) | BR112017002422B1 (Direct) |
| CA (1) | CA2957462C (Direct) |
| DK (1) | DK3177646T3 (Direct) |
| HR (1) | HRP20202024T1 (Direct) |
| HU (1) | HUE051919T2 (Direct) |
| LT (1) | LT3177646T (Direct) |
| RU (1) | RU2742691C2 (Direct) |
| SI (1) | SI3177646T1 (Direct) |
| WO (1) | WO2016020444A1 (Direct) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY176522A (en) | 2013-11-04 | 2020-08-13 | Ichnos Sciences SA | Production of t cell retargeting hetero-dimeric immunoglobulins |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| JP6991979B2 (ja) | 2016-02-05 | 2022-03-04 | オリオニス バイオサイエンシズ ビーブイ | Ｃｄ８結合物質 |
| CN110603266A (zh) | 2016-06-02 | 2019-12-20 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| WO2018054484A1 (en) | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| WO2018155611A1 (ja) | 2017-02-24 | 2018-08-30 | 中外製薬株式会社 | 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法 |
| EP3366704A1 (en) | 2017-02-28 | 2018-08-29 | Affimed GmbH | Antibodies specific for mmp1/hla-a2 complex |
| JP7164544B2 (ja) | 2017-04-11 | 2022-11-01 | インヒブルクス インコーポレイテッド | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| CA3064163A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Therapeutics AG | Novel anti-cd3 antibodies |
| US11472880B2 (en) | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
| KR101973060B1 (ko) * | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3502140A1 (en) * | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
| US20200399373A1 (en) * | 2018-02-14 | 2020-12-24 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule and combination |
| AU2019235523B2 (en) * | 2018-03-14 | 2025-12-18 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
| CN112218686A (zh) | 2018-04-11 | 2021-01-12 | 印希比股份有限公司 | 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途 |
| EP3802608B1 (en) * | 2018-05-24 | 2025-04-30 | Janssen Biotech, Inc. | Anti-cd3 antibodies and uses thereof |
| WO2020023553A1 (en) * | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| KR20210049863A (ko) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도 |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Ｄｌｌ３シングルドメイン抗体およびその治療用組成物 |
| AU2019439345B2 (en) * | 2019-03-29 | 2024-08-08 | Green Cross Corporation | Fusion protein comprising anti-mesothelin antibody, anti-CD3 antibody or anti-EGFR antibody, bispecific or trispecific antibody comprising same, and uses thereof |
| EP4097129A1 (en) | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| TWI888487B (zh) * | 2020-02-14 | 2025-07-01 | 日商協和麒麟股份有限公司 | 與ｃｄ３結合之雙特異性抗體 |
| PH12022500023A1 (en) | 2020-05-27 | 2024-03-11 | Janssen Biotech Inc | Proteins comprising cd3 antigen binding domains and uses thereof |
| KR20230079409A (ko) * | 2020-09-29 | 2023-06-07 | 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 | 항-cd3 항체 및 이의 용도 |
| AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CN117321078A (zh) | 2021-04-30 | 2023-12-29 | 豪夫迈·罗氏有限公司 | 针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药 |
| WO2022263507A1 (en) | 2021-06-17 | 2022-12-22 | Boehringer Ingelheim International Gmbh | Novel tri-specific binding molecules |
| CA3244652A1 (en) | 2021-12-31 | 2025-05-22 | Kyinno Biotechnology Co., Ltd. | Anti-GPRC5D Antibodies and Their Use |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| CA3251878A1 (en) | 2022-03-23 | 2023-09-28 | Genentech, Inc. | COMBINED TREATMENT COMBINING AN ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODY AND CHEMOTHERAPY |
| EP4508081A1 (en) | 2022-04-13 | 2025-02-19 | F. Hoffmann-La Roche AG | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2024152963A1 (zh) * | 2023-01-18 | 2024-07-25 | 贝达药业股份有限公司 | 抗cd3的人源化抗体及其应用 |
| WO2025224084A1 (en) | 2024-04-22 | 2025-10-30 | Engimmune Therapeutics Ag | Proteins comprising t cell receptor constant domains |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1297090B1 (it) * | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
| MXPA01009074A (es) * | 1999-03-09 | 2002-03-27 | Zymogenetics Inc | Nuevo ligando zalfa11 de citocina. |
| DE60124912T2 (de) | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| US8101722B2 (en) | 2004-02-16 | 2012-01-24 | Micromet Ag | Less immunogenic binding molecules |
| EP2222697B1 (en) * | 2007-11-01 | 2012-12-05 | Perseid Therapeutics LLC | Immunosuppressive polypeptides and nucleic acids |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| AU2012233313C1 (en) * | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
| MY173899A (en) * | 2011-05-21 | 2020-02-26 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| EP2938636A2 (en) * | 2012-12-28 | 2015-11-04 | AbbVie Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| HUE054057T2 (hu) * | 2013-08-07 | 2021-08-30 | Affimed Gmbh | EGFRvIII specifikus antitest-kötõhelyek |
| US9212225B1 (en) * | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
-
2015
- 2015-02-11 EP EP15154772.6A patent/EP2982693A1/en not_active Withdrawn
- 2015-08-05 BR BR112017002422-5A patent/BR112017002422B1/pt active IP Right Grant
- 2015-08-05 LT LTEP15756850.2T patent/LT3177646T/lt unknown
- 2015-08-05 RU RU2017105120A patent/RU2742691C2/ru active
- 2015-08-05 CA CA2957462A patent/CA2957462C/en active Active
- 2015-08-05 HR HRP20202024TT patent/HRP20202024T1/hr unknown
- 2015-08-05 EP EP15756850.2A patent/EP3177646B1/en active Active
- 2015-08-05 HU HUE15756850A patent/HUE051919T2/hu unknown
- 2015-08-05 AU AU2015299039A patent/AU2015299039B2/en active Active
- 2015-08-05 DK DK15756850.2T patent/DK3177646T3/da active
- 2015-08-05 CN CN201580054757.1A patent/CN107001468B/zh active Active
- 2015-08-05 WO PCT/EP2015/068070 patent/WO2016020444A1/en not_active Ceased
- 2015-08-05 SI SI201531457T patent/SI3177646T1/sl unknown
- 2015-08-05 JP JP2017506890A patent/JP6669722B2/ja active Active
- 2015-08-06 US US14/820,462 patent/US10066015B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529067A5 (Direct) | ||
| RU2017105120A (ru) | Cd3-связывающий домен | |
| JP2016536322A5 (Direct) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| FI4050034T3 (fi) | Cd3:een sitoutuvia vasta-aineita | |
| HRP20210739T1 (hr) | Molekule koje vežu antigen i sadrže trimer obitelji tnf liganada | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| JP2020517287A5 (Direct) | ||
| RU2015129762A (ru) | ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| HRP20161656T4 (hr) | Sredstva za vezanje na cd33 | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| RU2019100481A (ru) | Биспецифические антитела-ингибиторы контрольных точек | |
| JP2014158485A5 (Direct) | ||
| JP2017504578A5 (Direct) | ||
| RU2022102446A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2019501883A5 (Direct) | ||
| JP2018527919A5 (Direct) | ||
| JP2017029157A5 (Direct) | ||
| JP2019506841A5 (Direct) | ||
| JP2016196468A5 (Direct) | ||
| JP2020510659A5 (Direct) | ||
| FI3328893T3 (fi) | Mesoteliinia ja cd3:a sitovia bispesifisiä vasta-ainekonstrukteja | |
| JP2018502572A5 (Direct) | ||
| JP2020500510A5 (Direct) |